Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003

Clin Cancer Res. 2003 Feb;9(2):551-4.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Imidazoles
  • Matrix Metalloproteinases / metabolism*
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy
  • Neovascularization, Pathologic
  • Organic Chemicals*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Organic Chemicals
  • N-((2S)-2-mercapto-1-oxo-4-(3,4,4- trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3- dimethyl-L-Valinamide
  • Matrix Metalloproteinases